MDXG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MiMedx Group Inc. (MDXG) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown strong financial growth in the latest quarter, the technical indicators and options data suggest a lack of immediate upward momentum. Additionally, recent analyst ratings reflect uncertainty due to regulatory changes, and there are no significant positive catalysts or trading signals to suggest an immediate entry point.
The technical indicators are mixed. The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of $5.131, with resistance at $5.273 and support at $4.99. Overall, the technical setup does not strongly favor a buy at this time.
The company has shown strong financial performance in Q3 2025, with revenue up 35.30% YoY, net income up 106.89% YoY, EPS up 120.00% YoY, and gross margin improving to 83.44%. Analysts expect long-term growth in the surgical recovery business.
Analysts have lowered price targets, and the stock is expected to face near-term headwinds.
In Q3 2025, MiMedx reported strong financial growth: Revenue increased to $113.73M (up 35.30% YoY), Net Income rose to $16.75M (up 106.89% YoY), EPS improved to $0.11 (up 120.00% YoY), and Gross Margin increased to 83.44% (up 2.33% YoY). These results demonstrate robust operational performance.
Analysts have lowered price targets recently due to regulatory uncertainty. Cantor Fitzgerald reduced the target to $8 (Overweight), Craig-Hallum to $10 (Buy), Lake Street to $10 (Buy), Northland to $10 (Outperform), and Mizuho to $10 (Outperform). Despite near-term challenges, analysts remain optimistic about long-term growth in the surgical recovery segment.
